Completed Enrollment
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes (ACHIEVE-J)
J2A-JE-GZPE - ClinicalTrials.gov - NCT06010004
The purpose of this study is to determine the long-term safety of the study intervention orforglipron as monotherapy or in combination with oral antihyperglycemic medication.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Type 2 DiabetesWhat the trial is testing?
OrforglipronCould I receive a Placebo?
NoEnrollment Goal
399Trial Dates
Sep 28, 2023 - Jun 2025How long will I be in the trial?
The study will last about 58 weeks and may include up to 13 visits.Trial Phase
IIIKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Have Type 2 diabetes
Have overweight
Participants Must Not:
Have Type 1 diabetes
Have severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening, or between screening and randomization.
Have heart attack, stroke or congestive heart failure within 60 days prior to screening
Have pancreatitis
Lilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo